OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA
Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes
BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to better understand, compare, and predict patient outcomes, today announced the availability of its Systemic Lupus Erythematosus (SLE) registry for collaborations.
Lupus is a chronic autoimmune disease that can damage any part of the body, including skin, joints, and organs, and can be difficult to diagnose due to the variety of symptoms. The Lupus Foundation of America estimates 1.5 million Americans have a form of lupus, 70% or approximately 1 million have SLE. With no cure, early diagnosis and effective treatment are the best way to help reduce the damaging effects and improve patients’ quality of life.
The OM1 SLE registry is a continually updating database of more than 25,000 patients prospectively followed with deep clinical, laboratory and other data, such as measures of disease activity and treatment response. Using the registry, for example, OM1 researchers have identified subtypes of SLE that have different courses of disease and may respond differently to treatment.
“We are excited to collaborate with the broader Lupus stakeholder community. The high availability and depth of the registry data enables researchers, life sciences manufacturers, payers and other stakeholders to answer important questions around natural history, disease progression, and treatment outcomes– that have not been previously possible,” said Dr. Richard Gliklich, CEO of OM1. “Additionally, our ability to tap into data from almost another 400,000 lupus patients in the OM1 Intelligent Data Cloud, allows us to apply models and other advanced techniques aimed at bringing the right treatment to the right patient more quickly.”